{"id":"diovan-valsartan","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"2-3","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"1-2","effect":"Headache"},{"rate":"1-2","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1069","moleculeType":"Small molecule","molecularWeight":"435.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, preventing angiotensin II from binding and triggering vasoconstriction and aldosterone release. This leads to reduced peripheral vascular resistance, lower blood pressure, and decreased cardiac workload. It is commonly used in hypertension and heart failure management.","oneSentence":"Valsartan blocks angiotensin II receptors on blood vessels and the heart, causing vasodilation and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:17.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure (reduced ejection fraction)"},{"name":"Post-myocardial infarction with left ventricular dysfunction"}]},"trialDetails":[{"nctId":"NCT05168787","phase":"","title":"Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2020-08-13","conditions":"Heart Failure","enrollment":6558},{"nctId":"NCT07491718","phase":"NA","title":"Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-08-08","conditions":"Takotsubo Cardiomyopathy","enrollment":100},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05194111","phase":"PHASE1, PHASE2","title":"Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2022-08-11","conditions":"Heart Failure, Heart Dysfunction","enrollment":53},{"nctId":"NCT07465679","phase":"","title":"A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-28","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":500},{"nctId":"NCT07465653","phase":"PHASE1","title":"A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-19","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":12},{"nctId":"NCT07465666","phase":"","title":"A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-01","conditions":"Hypertension","enrollment":500},{"nctId":"NCT04153136","phase":"PHASE2","title":"The ENCHANTMENT HIV Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-09-11","conditions":"HIV/AIDS, Heart Failure With Preserved Ejection Fraction","enrollment":39},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT07444398","phase":"PHASE1","title":"Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial","status":"RECRUITING","sponsor":"Khawaja Danish Ali","startDate":"2026-01-01","conditions":"Decompensated Heart Failure","enrollment":130},{"nctId":"NCT06536309","phase":"PHASE4","title":"Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07","conditions":"Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis","enrollment":36},{"nctId":"NCT07417215","phase":"PHASE4","title":"The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF","status":"NOT_YET_RECRUITING","sponsor":"University Clinical Hospital Mostar","startDate":"2026-01-30","conditions":"Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis, Sacubitril/Valsartan","enrollment":60},{"nctId":"NCT05528419","phase":"PHASE4","title":"Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-02-06","conditions":"Atrial Fibrillation Recurrent, Hypertension","enrollment":320},{"nctId":"NCT07376265","phase":"","title":"A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-20","conditions":"Heart Failure","enrollment":1249},{"nctId":"NCT07379788","phase":"","title":"ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling","status":"RECRUITING","sponsor":"Rehab Werida","startDate":"2025-12-25","conditions":"Heart Failure","enrollment":180},{"nctId":"NCT03872778","phase":"PHASE1, PHASE2","title":"[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2019-05-24","conditions":"Neoplasms","enrollment":35},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT06142383","phase":"PHASE2","title":"A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-12","conditions":"Heart Failure","enrollment":136},{"nctId":"NCT06930885","phase":"PHASE3","title":"Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2025-06-12","conditions":"Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)","enrollment":7713},{"nctId":"NCT07356388","phase":"PHASE3","title":"FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan","status":"ACTIVE_NOT_RECRUITING","sponsor":"kewen Chen,MD","startDate":"2025-01-30","conditions":"Kidney Transplantation Recipients, Proteinuria Patients","enrollment":54},{"nctId":"NCT07347925","phase":"","title":"Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2026-01-10","conditions":"Heart Failure","enrollment":140},{"nctId":"NCT05609513","phase":"NA","title":"Integration of Hypertension Management in HIV Care in Uganda","status":"COMPLETED","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2023-02-06","conditions":"HIV/AIDS, Hypertension","enrollment":87421},{"nctId":"NCT07341893","phase":"NA","title":"Sacubitril-valsartan in Patients With Heart Failure.","status":"RECRUITING","sponsor":"Damanhour University","startDate":"2025-08-01","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT06237309","phase":"PHASE2","title":"REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-11","conditions":"Heart Failure","enrollment":89},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT07331389","phase":"PHASE1","title":"A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-09-24","conditions":"Overweight Subject, Healthy Subjects","enrollment":111},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT07327749","phase":"PHASE4","title":"Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2022-10-01","conditions":"Hypertension","enrollment":59},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT05991284","phase":"PHASE4","title":"Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2024-02-29","conditions":"Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation","enrollment":84},{"nctId":"NCT03744975","phase":"PHASE2","title":"PDD in Type 2 Diabetes w/wo Diastolic Dysfunction","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Diastolic Dysfunction","enrollment":72},{"nctId":"NCT06643819","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-10-14","conditions":"Essential Hypertension","enrollment":324},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05498181","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-10-11","conditions":"Hemodialysis","enrollment":100},{"nctId":"NCT07241338","phase":"PHASE4","title":"Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Jing Liu","startDate":"2025-11","conditions":"Hypertension","enrollment":104},{"nctId":"NCT05989503","phase":"PHASE4","title":"Initiation of ARNi and SGLT2i in Patients With HFrEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2023-08-04","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":62},{"nctId":"NCT04023227","phase":"PHASE4","title":"Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-10","conditions":"Chagas Disease, Heart Failure","enrollment":918},{"nctId":"NCT06149104","phase":"PHASE3","title":"A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-04","conditions":"Heart Failure","enrollment":8},{"nctId":"NCT05279742","phase":"PHASE1, PHASE2","title":"Enhancing the Natriuretic Peptide System in HFpEF","status":"ENROLLING_BY_INVITATION","sponsor":"Horng Chen","startDate":"2022-11-04","conditions":"Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT06693674","phase":"PHASE3","title":"Effect of Sacubitril-Valsartan on Cardiac Structure and Function","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-03","conditions":"Congenital Heart Disease","enrollment":45},{"nctId":"NCT07192341","phase":"NA","title":"Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2025-09-27","conditions":"Sacubitril/Valsartan, Prosthetic Heart Valve, Heart Failure","enrollment":220},{"nctId":"NCT07197372","phase":"","title":"Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-30","conditions":"ARNI, Pediatric Dilated Cardiomyopathy, ACE Inhibitor","enrollment":70},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT03508739","phase":"PHASE3","title":"Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition","status":"SUSPENDED","sponsor":"University of Pennsylvania","startDate":"2018-06-01","conditions":"Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension","enrollment":25},{"nctId":"NCT01764178","phase":"PHASE1","title":"To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2013-01-22","conditions":"Hyperlipidemia, Hypertension","enrollment":52},{"nctId":"NCT07157527","phase":"","title":"Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":"Left Ventricular Diastolic Function","enrollment":70},{"nctId":"NCT06704633","phase":"PHASE4","title":"Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania","status":"NOT_YET_RECRUITING","sponsor":"Martin Rohacek","startDate":"2026-01-05","conditions":"Heart Failure","enrollment":238},{"nctId":"NCT06917664","phase":"PHASE4","title":"Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-06-05","conditions":"Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor","enrollment":220},{"nctId":"NCT07139405","phase":"PHASE2","title":"TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT","status":"NOT_YET_RECRUITING","sponsor":"Myopharm Limited","startDate":"2026-02","conditions":"Type 2 Diabetes (T2DM)","enrollment":90},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05636774","phase":"NA","title":"Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2022-12-12","conditions":"Patients With Advanced Cancer Receiving Specialized Palliative Care","enrollment":97},{"nctId":"NCT07130175","phase":"NA","title":"Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)","status":"COMPLETED","sponsor":"Qian Feng","startDate":"2022-12-31","conditions":"Polymorphic Ventricular Tachycardia, Heart Failure","enrollment":118},{"nctId":"NCT07116863","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Kyungdong Pharmaceutical Co., Ltd.","startDate":"2022-06-21","conditions":"Essential Hypertension","enrollment":286},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":"PreDiabetes, Impaired Glucose Tolerance, Obesity","enrollment":90},{"nctId":"NCT07088471","phase":"","title":"Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Connolly Hospital Blanchardstown","startDate":"2024-11-01","conditions":"Heart Failure and Reduced Ejection Fraction","enrollment":334},{"nctId":"NCT03738878","phase":"PHASE4","title":"Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-11-15","conditions":"Hypertension","enrollment":4},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT04055428","phase":"PHASE2","title":"NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-15","conditions":"Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance","enrollment":200},{"nctId":"NCT05976230","phase":"","title":"Special Drug Use Surveillance of Entresto Tablets (Hypertension)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-04","conditions":"Hypertension","enrollment":1125},{"nctId":"NCT03553810","phase":"PHASE2","title":"Role of ARNi in Ventricular Remodeling in Hypertensive LVH","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-04-12","conditions":"Hypertensive Heart Disease","enrollment":80},{"nctId":"NCT07023016","phase":"PHASE2, PHASE3","title":"Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"National Heart Institute, Egypt","startDate":"2023-11-01","conditions":"Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD)","enrollment":515},{"nctId":"NCT05353166","phase":"PHASE2","title":"REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-06-30","conditions":"Heart Failure","enrollment":59},{"nctId":"NCT05170061","phase":"PHASE3","title":"24 Hour Ambulatory Cardiac Oxygen Consumption","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2013-02","conditions":"Hypertension","enrollment":26},{"nctId":"NCT03535376","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Valsartan","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT03686657","phase":"PHASE1, PHASE2","title":"Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","status":"NOT_YET_RECRUITING","sponsor":"ARKAY Therapeutics","startDate":"2025-10-10","conditions":"Type 2 Diabetes, High Blood Pressure, Arthritis","enrollment":115},{"nctId":"NCT03928158","phase":"PHASE2","title":"LCZ696 in Advanced LV Hypertrophy and HFpEF","status":"COMPLETED","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2019-05-31","conditions":"Heart Failure, Essential Hypertension","enrollment":61},{"nctId":"NCT04491136","phase":"PHASE4","title":"Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-11","conditions":"Heart Failure","enrollment":201},{"nctId":"NCT03785405","phase":"PHASE3","title":"Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-02","conditions":"Heart Failure","enrollment":216},{"nctId":"NCT04164732","phase":"PHASE2","title":"Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-01-08","conditions":"Cardiomyopathy, Hypertrophic","enrollment":46},{"nctId":"NCT06625346","phase":"","title":"Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.","status":"RECRUITING","sponsor":"The Searle Company Limited Pakistan","startDate":"2024-09-28","conditions":"Hypertension","enrollment":420},{"nctId":"NCT04971720","phase":"PHASE2, PHASE3","title":"PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-18","conditions":"Obesity, Cardiovascular Diseases, Hypertension","enrollment":160},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT06922253","phase":"PHASE1","title":"Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-12-28","conditions":"Chronic Heart Failure","enrollment":48},{"nctId":"NCT06900803","phase":"NA","title":"Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-07","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence","enrollment":200},{"nctId":"NCT06053580","phase":"PHASE2","title":"Repurposing Valsartan May Protect Against Pulmonary Hypertension","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-02-28","conditions":"Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction","enrollment":60},{"nctId":"NCT05465031","phase":"PHASE4","title":"Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","status":"RECRUITING","sponsor":"Silesian Centre for Heart Diseases","startDate":"2024-04-17","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":600},{"nctId":"NCT06863987","phase":"PHASE3","title":"A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02-05","conditions":"Essential Hypertension","enrollment":342},{"nctId":"NCT03988634","phase":"PHASE3","title":"Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-29","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF)","enrollment":467},{"nctId":"NCT04637152","phase":"PHASE2","title":"Sacubitril/Valsartan in Resistant Hypertension","status":"COMPLETED","sponsor":"Hospital Geral Roberto Santos","startDate":"2020-11-11","conditions":"Resistant Hypertension, Blood Pressure","enrollment":80},{"nctId":"NCT06655480","phase":"PHASE2","title":"Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF","status":"NOT_YET_RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2025-03-18","conditions":"HFpEF, LVDD, Myocardial Fibrosis","enrollment":50},{"nctId":"NCT05593575","phase":"PHASE2","title":"Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-03-22","conditions":"Diabetic Kidney Disease","enrollment":305},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT03760588","phase":"PHASE2","title":"Prevention of Cardiac Dysfunction During Breast Cancer Therapy","status":"COMPLETED","sponsor":"Torbjorn Omland","startDate":"2019-01-31","conditions":"Breast Cancer Female, Heart Failure","enrollment":138},{"nctId":"NCT04149990","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI","status":"TERMINATED","sponsor":"Jacob Moller","startDate":"2018-10-12","conditions":"Myocardial Infarction, Diastolic Dysfunction","enrollment":51},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT06771245","phase":"PHASE3","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-01-24","conditions":"Mild-to-moderate Essential Hypertension","enrollment":606},{"nctId":"NCT06716970","phase":"PHASE3","title":"QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-12-30","conditions":"Essential Hypertension","enrollment":810},{"nctId":"NCT06712030","phase":"PHASE3","title":"Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Puerta de Hierro University Hospital","startDate":"2025-01","conditions":"Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","enrollment":114},{"nctId":"NCT05508035","phase":"PHASE3","title":"The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction","status":"RECRUITING","sponsor":"John Paul II Hospital, Krakow","startDate":"2023-07-13","conditions":"Heart Failure with Moderately Reduced Ejection Fraction","enrollment":666},{"nctId":"NCT06604897","phase":"","title":"Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis","startDate":"2023-01-31","conditions":"Essential Hypertension","enrollment":1405},{"nctId":"NCT04587947","phase":"NA","title":"Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study","status":"COMPLETED","sponsor":"St. Josefs-Hospital Wiesbaden GmbH","startDate":"2020-04-01","conditions":"Heart Failure Patients","enrollment":63},{"nctId":"NCT06090487","phase":"NA","title":"Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-02-01","conditions":"Heart Failure","enrollment":30},{"nctId":"NCT06283420","phase":"","title":"Metabolic Response to the Initiation of Heart Failure Therapy","status":"RECRUITING","sponsor":"Vojtech Melenovsky, MD, PhD","startDate":"2024-08-23","conditions":"Heart Failure","enrollment":120},{"nctId":"NCT05164653","phase":"PHASE4","title":"Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saga University","startDate":"2021-12-27","conditions":"Heart Failure","enrollment":400},{"nctId":"NCT02884206","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-23","conditions":"Chronic Heart Failure (CHF)","enrollment":592},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6107,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Diovan (Valsartan)","genericName":"Diovan (Valsartan)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan blocks angiotensin II receptors on blood vessels and the heart, causing vasodilation and reducing blood pressure. Used for Hypertension, Heart failure (reduced ejection fraction), Post-myocardial infarction with left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}